The Cystic Fibrosis Transmembrane Conductance Regulator pipeline drugs market research report outlays comprehensive information on the Cystic Fibrosis Transmembrane Conductance Regulator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cystic Fibrosis Transmembrane Conductance Regulator pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Ophthalmology, Gastrointestinal, and Infectious Disease which include the indications Cystic Fibrosis, Keratoconjunctivitis Sicca (Dry Eye), Retinitis Pigmentosa (Retinitis), Diarrhea, Infectious Diarrhea, and Cholera. It also reviews key players involved in Cystic Fibrosis Transmembrane Conductance Regulator targeted therapeutics development with respective active and dormant or discontinued products.
The Cystic Fibrosis Transmembrane Conductance Regulator pipeline targets constitutes close to 63 molecules. Out of which, approximately 58 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 1, 11, 9, 2, 18, and 12 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 1, 3, and 1 molecule.
Cystic Fibrosis Transmembrane Conductance Regulator overview
Cystic fibrosis transmembrane conductance regulator (CFTR) is a protein that functions as a chloride channel across the membrane of cells that line various organs, including the lungs, pancreas, and intestines. It is crucial for regulating the movement of chloride ions and water in and out of these cells, playing a vital role in maintaining the proper balance of fluids and electrolytes.
For a complete picture of Cystic Fibrosis Transmembrane Conductance Regulator’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
